Boston Scientific announced it has obtained CE mark for the ACURATE Prime Aortic Valve System, the newest transcatheter aortic valve replacement, TAVR, technology in the company’s structural heart portfolio. The ACURATE Prime valve system is designed with several features to build upon the clinical performance of the ACURATE neo2 platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target raised to $92 from $90 at Citi
- Boston Scientific price target raised to $86 from $78 at Barclays
- Jefferies healthcare analyst to hold an analyst/industry conference call
- Boston Scientific Appoints New Director and Expands Board
- Boston Scientific removed from ‘Analyst Current Favorites’ at Raymond James